We observed that CLDN3 was silenced in the cell line recapitulating a more aggressive and therapy-resistant stage of prostate tumors (abl), but it was expressed in androgen sensitive prostate cancer cells (LNCaP), representing initial stages of prostate cancer development. This evidence concerns the gene CLDN3 and prostate carcinoma.